Institute for Pharmaceutical Microbiology, University of Bonn, Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.
Institute for Pharmaceutical Microbiology, University of Bonn, Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.
J Mol Biol. 2019 Aug 23;431(18):3520-3530. doi: 10.1016/j.jmb.2019.05.014. Epub 2019 May 14.
Natural product antibiotics usually target the major biosynthetic pathways of bacterial cells and the search for new targets outside these pathways has proven very difficult. Cell wall biosynthesis maybe the most prominent antibiotic target, and ß-lactams are among the clinically most relevant antibiotics. Among cell wall biosynthesis inhibitors, glycopeptide antibiotics are a second group of important drugs, which bind to the peptidoglycan building block lipid II and prevent the incorporation of the monomeric unit into polymeric cell wall. However, lipid II acts as a docking molecule for many more naturally occurring antibiotics from diverse chemical classes and likely is the most targeted molecule in antibacterial mechanisms. We summarize current knowledge on lipid II binding antibiotics and explain, on the levels of mechanisms and resistance development, why lipid II is such a prominent target, and thus provide insights for the design of new antibiotic drugs.
天然产物抗生素通常针对细菌细胞的主要生物合成途径,而在这些途径之外寻找新的靶点已被证明非常困难。细胞壁生物合成可能是最突出的抗生素靶标,而β-内酰胺类抗生素是临床上最相关的抗生素之一。在细胞壁生物合成抑制剂中,糖肽类抗生素是第二类重要药物,它们与肽聚糖构建块脂质 II 结合,阻止单体单元掺入聚合物细胞壁。然而,脂质 II 作为许多来自不同化学类别的天然存在的抗生素的 docking 分子,并且可能是抗菌机制中最受关注的分子。我们总结了关于脂质 II 结合抗生素的最新知识,并解释了为什么脂质 II 是如此突出的靶标,从机制和耐药性发展的角度来看,这为设计新的抗生素药物提供了思路。